Breaking News

Boehringer Ingelheim expands capabilities

Invests $22 million in development and manufacturing capabilities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim has expanded its biopharmaceutical development and manufacturing capabilities with an investment of approximately $22 million Euros at its cell culture and microbial sites in Biberach, Germany and in Vienna, Austria. These expansions enhance cell line development with the BI-HEX high expression system and microbial strain, as well as process development services for the contract manufacturing business. The company’s cGMP cell banking, process science, cell line development a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters